White Pine Capital LLC Makes New $2.24 Million Investment in AngioDynamics, Inc. $ANGO

White Pine Capital LLC purchased a new position in AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) during the 3rd quarter, Holdings Channel.com reports. The firm purchased 145,476 shares of the medical instruments supplier’s stock, valued at approximately $2,237,000.

Other hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in shares of AngioDynamics by 7.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 75,085 shares of the medical instruments supplier’s stock worth $1,155,000 after buying an additional 4,895 shares in the last quarter. State of Wyoming increased its holdings in shares of AngioDynamics by 166.6% in the 3rd quarter. State of Wyoming now owns 14,750 shares of the medical instruments supplier’s stock worth $227,000 after buying an additional 9,217 shares during the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of AngioDynamics during the 3rd quarter valued at about $40,000. Integrated Wealth Concepts LLC purchased a new stake in shares of AngioDynamics during the 2nd quarter valued at about $38,000. Finally, Corient Private Wealth LP purchased a new stake in shares of AngioDynamics during the 2nd quarter valued at about $134,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Insider Buying and Selling at AngioDynamics

In other news, CFO Stephen Trowbridge sold 23,615 shares of AngioDynamics stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $12.27, for a total transaction of $289,756.05. Following the completion of the sale, the chief financial officer directly owned 280,461 shares in the company, valued at approximately $3,441,256.47. This trade represents a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. HC Wainwright lowered their price target on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, October 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of AngioDynamics in a report on Friday, October 9th. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Zacks Research raised AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

View Our Latest Report on ANGO

AngioDynamics Stock Performance

Shares of ANGO stock opened at $11.87 on Monday. AngioDynamics, Inc. has a 52-week low of $9.39 and a 52-week high of $16.29. The firm has a market capitalization of $499.18 million, a P/E ratio of -15.22 and a beta of 0.30. The stock has a 50 day moving average price of $13.42 and a 200 day moving average price of $12.54.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The company had revenue of $80.92 million during the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.27 EPS for the current year.

About AngioDynamics

(Free Report)

AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.

See Also

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO – Free Report).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.